Demand for Gardasil leads to $650m investment in Merck’s operations

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/westend61)
(Image: Getty/westend61)

Related tags: Merck, Hpv vaccine, Vaccine, Manufacturing

Merck to invest in its North Carolina facilities as it expands production capacity to meet demand for its HPV vaccine Gardasil, and grow its packaging operations

The biopharmaceutical company will invest more than $650m (€583.18m) to build a new US production facility at its Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, North Carolina, as well as developing its packaging operations at its Wilson, North Carolina site.

The additional site in Durham will enable the company to expand its operations to meet the growing demand for Gardasil and Gardasil 9, recombinant human papillomavirus (HPV) vaccine used to prevent several cancers. The vaccine aims to prevent nine strains of HPV, including two that cause an estimated 70% of cervical cancers.

Merck, known as MSD outside the US and Canada, plans to design and build the 225,000-square-foot facility to produce an active ingredient for the vaccine Gardasil 9.

According to the company, the facility will be completed and online in three to four years, and is expected to create more than 400 jobs in the area.

Packaging operations at its Wilson site will see an investment of $30m to expand the facility and create 34 jobs.

Both projects in North Carolina will be facilitated by a Job Development Investment Grant approved by North Carolina’s Investment Committee. The project is estimated to add $3.1bn to the state’s economy over the 12-year term of the grant.

Gardasil leads vaccine sales for Merck​, as it brought in $838m in the first quarter of 2019. Sales of the vaccine increased 31% from $2.3bn in 2017 to $3.15bn in 2018.

Space for the additional production capacity comes as the company announced it will no longer manufacture varicella bulk drug product used in chickenpox and shingles vaccines at the Durham plant. The product will still be produced by the company solely at Merck’s West Point, Pennsylvania, facility as “market conditions” have changed.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us


View more